| Literature DB >> 21747744 |
Wan-Yu Lin1, Yi Lu1, Jui-Hsin Su2,3, Zhi-Hong Wen1, Chang-Feng Dai4, Yao-Haur Kuo5, Jyh-Horng Sheu1,6.
Abstract
Seven new cembranoids, sarcocrassocolides F-L (1-7), have been isolated from a soft coral Sarcophyton crassocaule. Their structures were determined by extensive spectroscopic analysis. Most new compounds exhibited significant cytotoxic activity against a limited panel of cancer cell lines, and the structure-activity relationship was studied. Compounds 1-7 were found to display significant in vitro anti-inflammatory activity in LPS-stimulated RAW264.7 macrophage cells by inhibiting the expression of the iNOS protein. Compound 4 was also found to effectively reduce the level of COX-2 protein.Entities:
Keywords: Sarcophyton crassocaule; anti-inflammatory activity; cytotoxic activity; soft coral
Mesh:
Substances:
Year: 2011 PMID: 21747744 PMCID: PMC3131557 DOI: 10.3390/md9060994
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Chart 1.Structures of Metabolites 1–7.
13C NMR data for compounds 1–7.
| 1 | 37.7, CH | 38.7, CH | 38.2, CH | 38.2, CH | 41.7, CH | 41.6, CH | 41.4, CH |
| 2 | 35.2, CH2 | 35.2, CH2 | 36.0, CH2 | 34.5, CH2 | 32.9, CH2 | 32.9, CH2 | 32.3, CH2 |
| 3 | 59.2, CH | 58.7, CH | 59.2, CH | 59.1, CH | 59.6, CH | 59.1, CH | 59.4, CH |
| 4 | 59.1, qC | 59.0, qC | 59.4, qC | 59.5, qC | 60.2, qC | 60.1, qC | 60.5, qC |
| 5 | 38.6, CH2 | 38.6, CH2 | 39.2, CH2 | 38.8, CH2 | 40.1, CH2 | 39.8, CH2 | 39.8, CH2 |
| 6 | 124.7, CH | 125.0, CH | 121.2, CH | 121.5, CH | 125.7, CH | 121.8, CH | 121.0, CH |
| 7 | 136.4, CH | 136.9, CH | 138.9, CH | 140.7, CH | 136.1, CH | 140.1, CH | 140.9, CH |
| 8 | 84.4, qC | 85.2, qC | 72.9, qC | 73.1, qC | 84.9, qC | 73.0, qC | 73.0, qC |
| 9 | 38.7, CH2 | 37.1, CH2 | 42.3, CH2 | 42.0, CH2 | 37.7, CH2 | 44.6, CH2 | 41.6, CH2 |
| 10 | 22.0, CH2 | 21.4, CH2 | 22.0, CH2 | 21.8, CH2 | 21.7, CH2 | 22.1, CH2 | 22.2, CH2 |
| 11 | 128.7, CH | 128.3, CH | 128.1, CH | 130.1, CH | 130.6, CH | 131.1, CH | 130.5, CH |
| 12 | 128.7, qC | 129.3, qC | 127.7, qC | 128.6, qC | 129.1, qC | 129.1, qC | 129.2, qC |
| 13 | 77.1, CH | 77.3, CH | 76.4, CH | 77.4, CH | 44.1, CH2 | 44.6, CH2 | 43.3, CH2 |
| 14 | 81.1, CH | 81.4, CH | 81.3, CH | 82.0, CH | 81.3, CH | 82.3, CH | 82.8, CH |
| 15 | 139.3, qC | 139.1, qC | 138.1, qC | 139.0, qC | 139.0, qC | 139.0, qC | 139.1, qC |
| 16 | 169.3, qC | 169.3, qC | 167.4, qC | 169.4, qC | 169.6, qC | 169.6, qC | 169.7, qC |
| 17 | 121.1, CH2 | 122.2, CH2 | 121.1, CH2 | 121.8, CH2 | 122.4, CH2 | 122.4, CH2 | 122.0, CH2 |
| 18 | 18.2, CH3 | 18.2, CH3 | 19.3, CH3 | 18.0, CH3 | 17.6, CH3 | 17.6, CH3 | 17.6, CH3 |
| 19 | 23.5, CH3 | 20.9, CH3 | 31.2, CH3 | 28.4, CH3 | 22.3, CH3 | 29.8, CH3 | 29.4, CH3 |
| 20 | 15.2, CH3 | 15.2, CH3 | 16.4, CH3 | 14.6, CH3 | 17.0, CH3 | 16.9, CH3 | 17.2, CH3 |
| OAc | 20.8, CH3 | 20.8, CH3 | 21.8, CH3 | 20.8, CH3 | |||
| 169.1, qC | 169.3, qC | 167.4, qC | 169.3, qC |
Spectra recorded at 125 MHz in CDCl3;
Spectra recorded at 100 MHz in CDCl3;
Deduced from DEPT.
1H NMR data for compounds 1–4.
| 1 | 3.10 dt (12.0, 2.5) | 3.13 dt (11.6, 2.4) | 3.11 dt (11.6, 2.8) | 3.04 ddd (11.2, 4.4, 2.4) |
| 2 | 1.84 ddd (14.5, 4.5,2.5) | 1.86 m | 1.82 ddd (15.2, 5.6, 2.8) | 1.85 m |
| 1.69 ddd (14.5, 12.0, 7.0) | 1.71 m | 1.72 m | 1.74 m | |
| 3 | 2.57 dd (6.5, 4.5) | 2.58 dd (6.8, 4.8) | 2.59 t (5.6) | 2.64 t (6.4) |
| 5 | 2.48 dd (14.5, 7.5) | 2.50 dd (15.2, 6.4); | 2.46 t (2.8) | 2.51 dd (14.4, 6.4) |
| 2.27 dd (14.5, 7.5) | 2.30 dd (15.2, 6.4) | 2.24 t (2.4) | 2.21 dd (11.6, 14.4) | |
| 6 | 5.49 dt (16.0, 7.5) | 5.52 dt (16.0, 6.4) | 5.51 m | 5.51 ddd (16.0, 8.0, 6.4) |
| 7 | 5.59 d (16.0) | 5.54 d (16.0) | 5.49 m | 5.60 d (16.0) |
| 9 | 2.22 ddd (14.5, 10.5, 5.0) | 1.91 m | 2.04 brs | 1.87 m |
| 1.37 dt (10.5, 5.0) | 1.56 m | 1.45 m | 1.60 m | |
| 10 | 2.39 ddt (17.0, 10.5, 5.0) | 2.04 m | 2.34 m | 2.15 m |
| 2.02 brs | 2.05 brs | 2.07 m | ||
| 11 | 5.28 dd (7.0, 1.0) | 5.30 brs | 5.30 d (8.4) | 5.41 m |
| 13 | 5.38 s | 5.37 s | 5.38 s | 5.40 brs |
| 14 | 4.62 t (3.0) | 4.57 t (2.8) | 4.60 t (2.8) | 4.59 dd (4.4, 2.4) |
| 17 | 6.30 d (2.5) | 6.32 d (2.4) | 6.31 d (2.0) | 6.30 d (2.4) |
| 5.64 d (2.5) | 5.67 d (2.4) | 5.65 d (2.0) | 5.62 d (2.4) | |
| 18 | 1.30 s | 1.31 s | 1.30 s | 1.32 s |
| 19 | 1.41 s | 1.35 s | 1.34 s | 1.30 s |
| 20 | 1.76 s | 1.73 s | 1.75 s | 1.71 s |
| 8-OOH | 7.42 s | |||
| 13-OAc | 2.02 s | 2.03 s | 2.02 s | 2.04 s |
Spectra recorded at 500 MHz in CDCl3;
Spectra recorded at 400 MHz in CDCl3;
J values (Hz) in parentheses.
Figure 11H-1H COSY and HMBC correlations for 1, 5 and 7.
Figure 2Key NOESY correlations for 1 and 2.
1H NMR data for compounds 5–7.
| 1 | 2.80 ddd (10.5, 5.0, 3.0) | 2.79 ddd (10.5, 5.5, 3.0) | 2.84 ddd (10.5, 5.5, 2.5) |
| 2 | 1.83 ddd (15.5, 10.5, 5.5) | 1.90 m | 1.83 m |
| 1.78 ddd (15.5, 7.0, 3.0) | 1.75 ddd (14.5, 7.5, 3.0) | ||
| 3 | 2.66 dd (7.0, 5.5) | 2.71 dd (7.5, 4.5) | 2.71 t (6.0) |
| 5 | 2.60 dd(14.0, 5.0) | 2.58 m | 2.58 dd (15.0, 6.0) |
| 2.15 dd (14.0, 6.5) | 2.15 ddd (26.0, 10.5, 3.0) | 2.12 dd (15.0, 8.0) | |
| 6 | 5.57 ddd (16.0, 6.5, 5.0) | 5.53 m | 5.53 ddd (16.0, 8.0, 6.0) |
| 7 | 5.58 d (16.0) | 5.55 d (16.0) | 5.61 d (16.0) |
| 9 | 2.04 m | 1.91 m | 1.73 m |
| 1.51 m | 1.57 m | ||
| 10 | 2.34 dt (13.5, 8.0) | 2.28 d (8.0) | 2.19 m |
| 2.02 m | 2.06 m | 2.09 m | |
| 11 | 5.23 brs | 5.24 t (6.5) | 5.29 t (7.0) |
| 13 | 2.58 dd (14.0, 5.0) | 2.59 dd (15.0, 5.5) | 2.55 dd (15.0, 6.0) |
| 2.25 dd (14.0, 8.0) | 2.26 d (8.0) | 2.35 dd (15.0, 6.0) | |
| 14 | 4.49 dt (8.0, 5.0) | 4.47 dt (8.0, 5.5) | 4.47 q (6.0) |
| 17 | 6.32 d (2.5) | 6.33 d (2.5) | 6.31 d (3.0) |
| 5.62 d (2.5) | 5.63 d (2.5) | 5.60 brs | |
| 18 | 1.32 s | 1.33 s | 1.34 s |
| 19 | 1.40 s | 1.32 s | 1.30 s |
| 20 | 1.67 s | 1.67 s | 1.65 s |
| 13-OAc |
Spectra recorded at 500 MHz in CDCl3;
Spectra recorded at 400 MHz in CDCl3;
J values (Hz) in parentheses.
Figure 3Key NOESY correlations for 5 and 7.
Cytotoxicity of compounds 1–7 (ED50 μM).
| 1 | 7.3 ± 1.7 | 15.0 ± 1.9 | 19.4 ± 2.4 | 18.4 ± 0.9 |
| 2 | 8.3 ± 1.4 | 16.5 ± 1.7 | 9.6 ± 2.7 | 18.9 ± 1.9 |
| 3 | 6.4 ± 2.0 | 13.5 ± 2.5 | 9.4 ± 2.5 | 18.7 ± 1.0 |
| 4 | 5.1 ± 1.2 | 5.8 ± 0.5 | 8.4 ± 1.5 | 6.4 ± 2.0 |
| 5 | >20 | >20 | >20 | >20 |
| 6 | 9.9 ± 4.0 | >20 | 10.2 ± 1.0 | >20 |
| 7 | >20 | >20 | >20 | >20 |
| Mitomycin-C | 0.44 ± 0.06 | 0.30 ± 0.06 | 0.30 ± 0.12 | 0.47 ± 0.12 |
Figure 4Effect of compounds 1–7 on iNOS and COX-2 proteins expression of RAW264.7 macrophage cells by immunoblot analysis: (A) Immunoblots of iNOS and β-actin; (B) Immunoblots of COX-2 and β-actin. The values are mean ± SEM (n = 6). Relative intensity of the LPS alone stimulated group was taken as 100 %.* Significantly different from LPS alone stimulated group (* P < 0.05). stimulated with LPS, stimulated with LPS in the presence of 1–7 (10 μM).